RANBAXY DAIICHI SANKYO MERGER

INTRODUCTION
• India’s largest pharmaceutical company.
•Incorporated in 1961
•Atul Sobti is currently Ranbaxy CEO and Managing Director
•Present Chairman- Dr. Tsutomu Une
•Exports its products to 125 countries
•Ground operations in 46 countries
•Manufacturing facilities in 7 countries.
•HQ: Gurgaon, Haryana.
HISTORY
 Started by Ranbir Singh and Gurbax Singh in 1937.
 In 1998, Ranbaxy entered the United States market

 Japanese company Daiichi Sankyo gained majority

control in 2008.
FINANCIALS
 2008- Global Sales of US $ 1,682 Million
 Growth of 4%.

 North America, the Company's largest market

contributed sales of US $ 449 Million
 India clocking sales of around US $ 300 Million

 Market share in India is 5%

MAJOR SETBACK
 December 2005, Ranbaxy's shares hit hard by a patent
ruling disallowing production of its own version of
Pfizer’s drug Lipitor.
 September 2008, the FDA issued two Warning Letters to
Ranbaxy and an Import Alert for generic drugs produced
by two manufacturing plants in India.
PRODUCT PORTFOLIO
 Anti-Infectives
 Cardiovascular

 Diabetes

 Dermatological

 Neuro-Psychiatry

 Pain management

 Gastro-Intestinal

 Nutritional

 A strong player in the NDDS segment.

 Biological formulations such as Verorab (Rabies

Vaccine) and Vaxigrip (Flu Vaccine),

MAJOR ALLIANCES / COLLABORATIONS
 Drug Discovery & Clinical Development –
GlaxoSmithKline
 (Anti-infective and Respiratory Segments)

 Drug Discovery Clinical Development – Merck

 Statin molecule out licensed to PPD, USA

 INTRODUCTION
 Japan based pharmaceutical company.
 Established in 2005 - merger of Sankyo Co., Ltd. and Daiichi
Pharmaceutical Co., Ltd.
 Head Office – Tokyo
 Leading company in the field of cardiovascular drugs.
 Workforce - 29,272 people (as of September 30,2009)
Capital - 50 billion yen
 U.S. subsidiary, Daiichi Sankyo, Inc. (DSI)
 European subsidiary, Daiichi Sankyo Europe GmbH (DSE)
HISTORY
 Sankyo –
 Established in 1913

 Daiichi Pharmaceutical –
 Established in 1918

 September 28, 2005 - DAIICHI SANKYO COMPANY, LIMITED

 2006 –
 Started operation of DAIICHI SANKYO HEALTHCARE CO., LTD.
 Started operations of DAIICHI SANKYO Inc.
 Started operations of Daiichi Sankyo Europe GmbH

 April 1, 2007- started operations as the newly formed DAIICHI SANKYO

Group
 RESEARCH AND DEVELOPMENT
 GEMRAD (Global Executive Meeting of Research
And Development) - top research and development
decision-making body.

 Research focusing on the six areas of cardiovascular

diseases, glucose metabolic disorders, infectious
diseases, cancer, immunity and allergies, and bones/joint
diseases.

 Core Development Areas: Thrombosis, Diabetes,

Malignant Neoplasm, and Autoimmune Diseases

 Franchise areas: Hypertension, Bacterial Infections, and

Hyperlipidemia / Atherosclerosis